started · updated
mRNA technology advancements offer potential for improved vaccine efficacy
Researchers at Johns Hopkins Medicine have discovered a method to potentially increase the efficiency of mRNA-based vaccines and treatments. By making a small adjustment to how mRNA is prepared, scientists found that cells can read instructions nearly twice as fast, leading to significantly higher protein production from the same amount of mRNA.
This discovery could allow for more effective treatments using smaller doses, which may benefit the development of vaccines for infectious diseases, autoimmune disorders, and cancer. While the findings are promising, further testing is required to ensure the method is safe and effective for human use.
In a related development, the biotechnology company Moderna is exploring mRNA technology to prevent cancer in high-risk individuals. The company is testing an experimental vaccine, mRNA-4194, designed for people with Lynch syndrome, a genetic condition that significantly increases the risk of colorectal and endometrial cancers. Clinical trials for this vaccine are currently in phase one, conducted in collaboration with the University of Oxford, to evaluate safety and immune response.
Entities
Johns Hopkins Medicine · Moderna · Stéphane Bancel · University of Oxford